Progesterone receptors prediction

Bardou, V.-J., Arpino, G., Elledge, R.M., Osborne, C.K., and Clark, G.M. 2003. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21, 1973-1979. 

Most steroid-sensitive cancers express specific cell surface receptors. Prednisone-sensitive lymphomas, estrogen-sensitive breast cancers, and prostatic cancers express specific receptors for corticosteroids, estrogens, and androgens, respectively. It is now possible to assay tumor specimens for steroid receptor content and to identify which individual patients are likely to benefit from hormonal therapy. Measurement of the estrogen receptor (ER) and progesterone receptor (PR) proteins in breast cancer tissue is now standard clinical practice. ER or PR positivity predicts response to hormonal therapy, whereas patients whose tumors are ER-negative generally fail to respond to such treatment. 

Most hormone-sensitive cancers will express hormone receptors that can be assayed on biopsy specimens. This allows the clinician to predict whether an individual patient is likely to benefit from hormonal therapy. For example, it is now standard to measure estrogen receptor (ER) and progesterone receptor (PR) content in breast cancer tissue. Patients with ER- or PR-positive tumors are more likely to respond to antiestrogen therapy compared with patients who lack these hormone receptors. 

Ravdin, P., Martino, S. and Osborne, C.K. (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligandbinding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer A Southwest Oncology Group study. International Journal of Cancer (Pred Oncol), 89, 111-117. 

In most situations, progesterone receptors are believed to be synthesized as the result of a fully functional ERP complex as an end product of estrogen-stimulated pathways in breast cancer tissue. The measurement of PRP, therefore, has also become important in predicting hormone responsiveness. Additionally, PRP is significant in predicting disease-free survival. 

M3. Manni, A., Arafah, B., and Pearson, O. H., Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer (Philadelphia) 46, 2838-2841 (1980). 

V2. Valavaara, R., Tuominen, J., and Johansson, R., Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer (Philadelphia) 66, 2264-2269 (1990). 

---